NCT00637078

Brief Summary

The objective of this study is to assess if the implementation of a treatment algorithm including initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination and subsequently a low dose DHP-CCB/statin combination will improve the management of hypertension/hypercholesterolemia compared to guidelines-base management at family practices.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for phase_4 hypertension

Timeline
Completed

Started Feb 2008

Typical duration for phase_4 hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 3, 2008

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 17, 2008

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

June 14, 2012

Status Verified

June 1, 2012

Enrollment Period

2.3 years

First QC Date

March 3, 2008

Last Update Submit

June 13, 2012

Conditions

Keywords

hypertensionhypercholesterolemiafamily physiciansfixed dose combination therapycluster randomized controlled trial

Outcome Measures

Primary Outcomes (1)

  • Proportion of subjects whose systolic BP [SBP] <140 mmHg and diastolic BP [DBP] <90 mmHg)or proportion whose cholesterol levels are at or below threshold based on their global artherosclerotic risk profile compared at the practice level.

    6 months

Secondary Outcomes (1)

  • Secondary measures include the change at 6 months in SBP and DBP and cholesterol levels. These outcomes will be compared at the practice level

    6 months

Study Arms (2)

1

ACTIVE COMPARATOR

Drug: Fix dose combination therapy

Other: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide

2

NO INTERVENTION

Guidelines based management

Interventions

initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • male or female subjects 18 years or older
  • documented diagnoses of hypertension and of hypercholesterolemia or current therapy for these conditions
  • uncontrolled hypertension (SBP \>140 mmHg or DBP \>90 mmHg) or cholesterol levels above their threshold based on their global atherosclerotic risk profile (based on ATP III assessment)
  • ability to give written informed consent

You may not qualify if:

  • ischemic heart disease, atrial fibrillation, chronic kidney disease and significant liver disease
  • currently prescribed 3 or more drugs to control blood pressure
  • currently prescribed 2 or more drugs to control hypercholesterolemia
  • participating in other hypertension/hypercholesterolemia studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Robarts Research Insititute

London, Ontario, N6A 5K8, Canada

Location

MeSH Terms

Conditions

HypertensionHypercholesterolemia

Interventions

AmlodipineSpironolactone

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsLactonesOrganic ChemicalsPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Ross Feldman, MD

    Deputy Director

    PRINCIPAL INVESTIGATOR
  • George Dresser, MD

    Co prinicipal investigator

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 3, 2008

First Posted

March 17, 2008

Study Start

February 1, 2008

Primary Completion

June 1, 2010

Study Completion

December 1, 2010

Last Updated

June 14, 2012

Record last verified: 2012-06

Locations